Ionophores as cancer chemotherapeutic agents

A method of treating cancer comprising administering to a mammal in need of such treatment, a pharmaceutical composition comprising an effective amount of ionophore or pharmaceutically acceptable salts thereof and an effective amount of transition metals.

A method of treating cancer comprising administering to a mammal in need of such treatment, a pharmaceutical composition comprising an effective amount of ionophore or pharmaceutically acceptable salts thereof, an effective amount of transition metals, and an effective amount of albumin.

A method of treating cancer comprising administering to a mammal in need of such treatment, a pharmaceutical composition comprising an effective amount of ionophore or pharmaceutically acceptable salts thereof, and an effective amount of polyunsaturated fatty acids.

A pharmaceutical composition for the treatment of cancer comprising an effective amount of ionophore or pharmaceutically acceptable salts thereof and a suitable pharmaceutical carrier.

A pharmaceutical composition for the treatment of cancer comprising an effective amount of ionophore or pharmaceutically acceptable salts thereof and an effective amount of transition metals and pharmaceutically acceptable carrier.

A pharmaceutical composition for the treatment of cancer comprising an effective amount of ionophore or pharmaceutically acceptable salts thereof, an effective amount of transition metals, and an effective amount of albumin and pharmaceutically acceptable carrier.

A pharmaceutical composition for the treatment of cancer comprising an effective amount of ionophore or pharmaceutically acceptable salts thereof, and an effective amount of polyunsaturated fatty acids and a pharmaceutically acceptable carrier.

A pharmaceutical composition for treating a disease state associated with uncontrolled cellular proliferation comprising:

• i. an ionophore or a pharmaceutically acceptable salt, prodrug or pharmaceutically active metabolite or a pharmaceutically acceptable salt of a metabolite or prodrug thereof, and
• ii. a pharmaceutically acceptable carrier.

A method of treating a disease state or disorder associated with uncontrolled cellular proliferation comprising administering to a subject in need thereof a therapeutically effective amount of an ionophore, or a pharmaceutically acceptable salt of a compound thereof;

• or a prodrug or pharmaceutically active metabolite of a compound thereof or a pharmaceutically acceptable salt of a prodrug thereof.